
Sign up to save your podcasts
Or


Dr. Jay Duker speaks about the results of the DAVIO trial which was a phase 1 trial investigating an intravitreal implant (EYP-1901) containg vorolanib (a VEGF and receptor blocker) in a bioerodible Durasert implant for the treatment of wet AMD.
By Keyvan Koushan, MD, FRCSC4.4
1111 ratings
Dr. Jay Duker speaks about the results of the DAVIO trial which was a phase 1 trial investigating an intravitreal implant (EYP-1901) containg vorolanib (a VEGF and receptor blocker) in a bioerodible Durasert implant for the treatment of wet AMD.

30,795 Listeners

18 Listeners

97 Listeners

2,441 Listeners

112,401 Listeners

56,702 Listeners

2 Listeners

4 Listeners

8 Listeners

10 Listeners

50 Listeners

11 Listeners

465 Listeners

19 Listeners

1 Listeners